News | August 10, 2022
Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
The cash consideration for the acquisition is US$ 18 million.
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
The company has strong product launches both in India and overseas
Arrow is the marketing partner in US
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The company received seven observations in the Form-483
Subscribe To Our Newsletter & Stay Updated
